您的位置:首页>>生化试剂>>小分子化合物>>10-2120 硼替佐米 Bortezomib 179324-69-7
Cat. Number
10-2120
Chemical Name
10-2120 硼替佐米 Bortezomib 179324-69-7
CAS Number
179324-69-7
Mol. Formula
C19H25BN4O4
Mol. Weight
384.25
Qty 1
5mg
Qty 2
25mg
Appearance
White solid
Application Notes
98% by TLC NMR (conforms)
Synonym
MG-341, PS-341,N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Solubility
Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 35 mg/ml).
Storage condition
-20℃
Stability
Stable for 2 years as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
References

Potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM).  Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma.3 Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved.4 Reversible. Cell permeable.

References/Citations
1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615
2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835
3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361
4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

Focus Biomolecules supplier, chemical structure of Bortezomib | Proteasome inhibitor | CAS 179324-69-7

 

硼替佐米  英文名称Bortezomib ,货号10-2120 上海惠诚提供5mg 25mg 硼替佐米 Bortezomib,美国focus原装进口,咨询电话021-60498804

硼替佐米  英文名称Bortezomib ,货号10-2120 上海惠诚提供5mg 25mg 硼替佐米 Bortezomib,美国focus原装进口,咨询电话021-60498804

 

下一个:CI-994上一个:阿西替尼 Axitinib
在线咨询 联系方式 二维码

服务热线

021-60498804

扫一扫,关注我们